FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $158 | -60.3% | 30,000 | -25.0% | 0.00% | -100.0% |
| Q4 2022 | $398 | -100.0% | 40,000 | 0.0% | 0.00% | -66.7% |
| Q3 2022 | $887,000 | +26.9% | 40,000 | +40.6% | 0.00% | +50.0% |
| Q2 2022 | $699,000 | -38.4% | 28,450 | 0.0% | 0.00% | -33.3% |
| Q1 2022 | $1,134,000 | -25.7% | 28,450 | +10.1% | 0.00% | -25.0% |
| Q4 2021 | $1,526,000 | +1.6% | 25,850 | +2.8% | 0.00% | 0.0% |
| Q3 2021 | $1,502,000 | -62.4% | 25,150 | -44.3% | 0.00% | -66.7% |
| Q2 2021 | $3,994,000 | +77.5% | 45,150 | +49.8% | 0.01% | +71.4% |
| Q1 2021 | $2,250,000 | -20.2% | 30,150 | 0.0% | 0.01% | -36.4% |
| Q4 2020 | $2,819,000 | +199.9% | 30,150 | +24.8% | 0.01% | +175.0% |
| Q3 2020 | $940,000 | +142.9% | 24,150 | -3.4% | 0.00% | +100.0% |
| Q3 2019 | $387,000 | -62.1% | 25,000 | -50.0% | 0.00% | -60.0% |
| Q2 2019 | $1,022,000 | +248.8% | 50,000 | +100.0% | 0.01% | +150.0% |
| Q4 2018 | $293,000 | – | 25,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |